What Is Lunsumio Velo, and Why Does It Matter? Lunsumio Velo (mosunetuzumab-axgb) is a new under-the-skin (subcutaneous) injection version of the anticancer medicine Lunsumio intravenous infusion. The ...
Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up PURPOSE: Unlike nodal follicular lymphoma (NFL), Primary cutaneous follicular lymphomas (PCFLs) rarely express Bcl-2 ...
While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Studies demonstrating high response rates and manageable safety profiles, along with FDA approvals, have supported bispecific antibodies as promising treatment options for follicular lymphoma. At the ...
"Random skin biopsies are utilized when there is a sufficiently high concern of the diagnosis in the patient and they do not have overt clinical findings suggestive of the diagnosis. In those cases, ...
Please provide your email address to receive an email when new articles are posted on . With new developments in the treatment of follicular lymphoma, such as chimeric antigen receptor T-cell ...
It’s not easy to hear you have follicular lymphoma. A subtype of non-Hodgkin lymphoma, this slow-growing, treatable cancer is considered rare, and may not be something you’ve heard of or know much ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback